GSK acquires anti-thrombotic agents from Sanofi-Aventis

GSK announced on September 7 the successful acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine, Fraxodi and Arixtra and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Aventis. As a part of this transaction, GSK assumes responsibility for ongoing Arixtra clinical trials.

The closing of this divesti...